HomeComparePRVB vs NNN

PRVB vs NNN: Dividend Comparison 2026

PRVB yields 8.01% · NNN yields 5.66%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PRVB wins by $8.5K in total portfolio value
10 years
PRVB
PRVB
● Live price
8.01%
Share price
$24.98
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.0K
Annual income
$1,328.87
Full PRVB calculator →
NNN
NNN REIT Inc.
● Live price
5.66%
Share price
$42.03
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.5K
Annual income
$2,622.67
Full NNN calculator →

Portfolio growth — PRVB vs NNN

📍 PRVB pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPRVBNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PRVB + NNN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PRVB pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PRVB
Annual income on $10K today (after 15% tax)
$680.54/yr
After 10yr DRIP, annual income (after tax)
$1,129.54/yr
NNN
Annual income on $10K today (after 15% tax)
$481.32/yr
After 10yr DRIP, annual income (after tax)
$2,229.27/yr
At 15% tax rate, NNN beats the other by $1,099.73/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PRVB + NNN for your $10,000?

PRVB: 50%NNN: 50%
100% NNN50/50100% PRVB
Portfolio after 10yr
$29.7K
Annual income
$1,975.77/yr
Blended yield
6.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

PRVB
Analyst Ratings
2
Buy
Consensus: Buy
Altman Z
8.7
Piotroski
2/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+6.9% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PRVB buys
0
NNN buys
0
No recent congressional trades found for PRVB or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPRVBNNN
Forward yield8.01%5.66%
Annual dividend / share$2.00$2.38
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6%
Portfolio after 10y$34.0K$25.5K
Annual income after 10y$1,328.87$2,622.67
Total dividends collected$10.7K$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: PRVB vs NNN ($10,000, DRIP)

YearPRVB PortfolioPRVB Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$11,501$800.64$10,735$614.96+$766.00PRVB
2$13,166$860.55$11,572$708.43+$1.6KPRVB
3$15,009$920.73$12,531$819.53+$2.5KPRVB
4$17,040$980.90$13,633$952.29+$3.4KPRVB
5$19,274$1,040.82$14,909$1,111.84+$4.4KPRVB
6$21,723$1,100.23$16,392$1,304.77+$5.3KPRVB
7$24,403$1,158.93$18,129$1,539.52+$6.3KPRVB
8$27,328$1,216.71$20,173$1,827.08+$7.2KPRVB
9$30,514$1,273.41$22,597$2,181.81+$7.9KPRVB
10$33,979$1,328.87$25,491$2,622.67+$8.5KPRVB

PRVB vs NNN: Complete Analysis 2026

PRVBStock

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Full PRVB Calculator →

NNNREIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this PRVB vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PRVB vs SCHDPRVB vs JEPIPRVB vs OPRVB vs KOPRVB vs MAINPRVB vs ADCPRVB vs EPRTPRVB vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.